Research brief · 2026-09-09
What Does Retatrutide Actually Do? What the Research Shows
Retatrutide, also known as LY3437943, is a synthetic peptide developed by Eli Lilly that activates three hormone receptors at once: GIP and GLP-1, the two targeted by tirzepatide, plus the glucagon receptor. Adding glucagon-receptor activity is theorized to raise energy expenditure on top of appetite suppression. It is not approved as a medicine anywhere in the world and exists only in clinical trials and a registered expanded-access program.
The only published trial of meaningful size is the Phase 2 study by Jastreboff and colleagues in the New England Journal of Medicine in 2023. It randomized 338 adults with obesity to several retatrutide dose arms or placebo, given weekly for 48 weeks under supervised escalation. Mean weight change at 48 weeks ranged from 8.7 percent at the lowest dose to 24.2 percent at the highest, versus 2.1 percent with placebo. Heart rate rose in a dose-dependent way, peaking around 24 weeks.
Beyond that, 33 studies listing retatrutide are registered on ClinicalTrials.gov, from Phase 1 pharmacology through a wide Phase 3 program in obesity, type 2 diabetes, kidney disease, knee osteoarthritis and sleep apnea. TRIUMPH-1, with 2,335 participants, reached primary completion in April 2026. As of this session, none of the Phase 3 trials had posted peer-reviewed or registry results.
Like others in this class, the trials excluded people with a history of pancreatitis or medullary thyroid cancer. A registered expanded-access program suggests the sponsor considers the drug close to a filing decision, but expanded access is not approval.
The unknowns are large: whether the Phase 2 effect holds in Phase 3, cardiovascular and kidney safety at scale, what happens after stopping, and the long-term meaning of the heart-rate increase. There is no approved dose for any use, and any product claiming to contain retatrutide outside a registered trial is not a legitimate source of the studied drug. Questions about weight-management medication belong with a physician.
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
- New England Journal of Medicine 2023
- ClinicalTrials.gov NCT04881760, retatrutide Phase 2 obesity trial, n=338
- ClinicalTrials.gov registry record 2022
- ClinicalTrials.gov NCT05929066, TRIUMPH-1 Phase 3 trial in obesity and overweight, n=2,335
- ClinicalTrials.gov registry record 2026
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.